Welcome to European Tribune. It's gone a bit quiet around here these days, but it's still going.
Display:
EPIDEMIC! not that one, the other one.
Advocacy blitz targets Medicare coverage of obesity treatment
Advocates say the drug carveout stems from lingering cultural stigma around obesity and a societal view that weight problems are a personal failure. Obesity was recognized as a disease by the American Medical Association in 2013, and the incidence of obesity has grown over time. The bipartisan bill, sponsored by Ron Kind, D-Wis., in the House and Thomas R. Carper, D-Del., in the Senate, has 117 co-sponsors between the two chambers.

About 42 percent of U.S. adults were considered obese in 2018, according to the Centers for Disease Control and Prevention. Obesity is a risk factor for many other top chronic diseases, including diabetes, heart disease and stroke. Annual obesity-related medical costs are estimated at $147 billion to $210 billion.
[...]
The drug industry is also deeply invested in the obesity field, and it stands to gain access to the $102 billion Part D drug market if the Medicare ban is lifted. Insulin and weight loss drug manufacturers like Novo Nordisk and Eli Lilly donate cash to many advocacy groups, politicians and medical research projects associated with obesity treatments, including Kind and Carper. ... "Senator Carper's Treat and Reduce Obesity Act has a robust group of bipartisan cosponsors and widespread support from groups representing American families struggling with obesity," a spokesman for Carper said. "UNLEASHING federal Medicare dollars for treatments against obesity would help millions of Americans lead longer and healthier lives."

reference
FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market
-- Why Was Belviq Recalled?
FDA | Questions and Answers about FDA's Initiative Against Contaminated Weight Loss Products
-- Why was Fen-Phen recalled?
Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications
novel substituents into the fentanyl structure a/o 2014
by Cat on Fri Dec 3rd, 2021 at 06:23:07 PM EST
[ Parent ]

Others have rated this comment as follows:

Display:

Top Diaries

Occasional Series